Episodios
-
Sarah Boyce from Avidity Biosciences and Piratip Pratumsuwan from RTW Investments explore the strategic decisions and innovations that have driven Avidity's success. They cover her approach to overcoming the challenges of scaling a biotech company, the impact of Avidity’s groundbreaking work on treating rare genetic disorders, and Sarah’s vision for the future of RNA-based therapies.
PODCAST TEAM
Producer: Devon Leaver
Technical Director: Joseph Sebring
Editor: Dominique Guerra
Featuring: Sarah Boyce, President and CEO of Avidity Biosciences, and Piratip Pratumsuwan, Managing Director; Research Analyst at RTW Investments.
LINKEDIN
Love our podcast? Follow us on LinkedIn at RTW Investments, LP and check out our website for the latest updates and insights.
DISCLAIMER
This interview and testimonial was given by Sarah Boyce, CEO of Avidity Biosciences, a company in which RTW has made an equity investment on behalf of its managed funds. No compensation was provided to Ms. Boyce.
-
Mark McKenna from Prometheus Biosciences and Josh Kennedy-Smith from RTW Investments tell us about the white-knuckle ride that is building a pharmaceutical start-up, their passion for providing better care solutions for patients, the recent deal with Merck and the power of a strong partnership with your investor.
Host: Josh Baldwin, RTW Investments
Featuring: Mark McKenna, CEO of Prometheus Biosciences and Josh Kennedy-Smith, Managing Director; Research Analyst of RTW Investments
-
¿Faltan episodios?
